This template is based on the manuscript specifications described at the journal's website (https://ekff-ge.com/guidelines/en/).

Please read the instructions below and use this template to write your manuscript.

INSTRUCTIONS:

1. DEADLINE / EDITING PROCESS: please visit the conference website and ensure that your manuscript is prepared and submitted before the deadline set by the Organising Committee
2. TITLE: please use up to 20 words and aim for clarity
3. AUTHOR(S): please provide the author(s) name(s) in full (i.e., name and surname), and please underline the surname of each author (this is particularly important for the correct indexing of the paper in international databases)
4. AFFILIATIONS: please provide the affiliations of each and every author, including the town/city and country
5. CORRESPONDING AUTHOR: please provide the corresponding author's details (name, affiliation, address, email, and telephone); the corresponding author bears complete responsibility in ensuring he/she has the consent of all co-authors and spells their details correctly (names, surnames, ORCIDs, and affiliations) in the submitted manuscript
6. ORCIDs: please provide the ORCID of each and every author; the details on the ORCID webpage(s) need to match the details of the author(s) as appearing in the manuscript, particularly in terms of the name(s) and surname(s)
7. ABSTRACT: please provide an unstructured abstract as a single paragraph if your manuscript describes a review or a keynote speech; please provide a structured abstract as "Background", "Aim", "Methodology", "Result", "Conclusion" if your manuscript describes the findings of research; the word limit is 200 words
8. KEYWORDS: please provide five keywords, separated by comma
9. MAIN TEXT: please provide the main text of your manuscript (minimum length: 500 words; maximum length: 1,200 words); if your manuscript describes the findings of research, the main text should be structured as "Introduction", "Methodology", "Results", "Discussion", "Conclusion"; if your manuscript is describing a review or summarizing an invited talk (applicable for keynote speakers *etc.*), then the structure of its main text can be freely defined by the author(s)
10. ACKNOWLEDGMENTS: please provide clearly written acknowledgments for any help and/or funding received from individuals or institutions
11. CONFLICT OF INTEREST STATEMENT: this is mandatory to declare; if no conflicts of interest exist, please simply write "None to declare."
12. REFERENCES: please note that only up to 10 references are allowed; see examples on their formatting in the template below and mimic them; references should be numbered in the main text (as numbers in brackets: i.e. [1], [2] etc.) and listed under the REFERENCES section in the order of their appearance in the main text
13. TABLE or FIGURE: please note that each manuscript can contain **either** one Table **or** one Figure, accompanied by a detailed legend; in the case of the Figure, multi-panelling is allowed, as long as the legend is appropriately descriptive

Manuscript number: …; **Received:** …; **Accepted:** …; **Category:** …

--- --- --- --- --- --- --- --- --- [please do not edit or delete anything above this line; for editorial use only] --- --- --- --- --- --- --- --- ---

Example of the manuscript title text that must be replaced appropriately and that should not exceed 20 words

Name Surname[1], Name Surname[2], …[X], Name Surname[99,*]

[1]Department of Something, College of Something Else, University of Somewhere, City, Country
[2]Department of Something, College of Something Else, University of Somewhere, City, Country
[X]…
[99]Department of Something, College of Something Else, University of Somewhere, City, Country

***Corresponding author:** Name Surname, Department of Something, College of Something Else, University of Somewhere, City, Country; Tel.: +XX-XXXXXXXXXX; E-mail: somenone@somewhere.com

ORCIDs: XXXX-XXXX-XXXX-XXXX (N. Surname); XXXX-XXXX-XXXX-XXXX (N. Surname); XXXX-XXXX-XXXX-XXXX (N. Surname)

ABSTRACT: Please add your unstructured abstract here if your manuscript is describing a review or a keynote speech and make sure it is written as a single paragraph, without headings, and without exceeding the 200-word limit. Please add your structured abstract here and make sure it is written as a single

 © 2025 PHARMAKON-Press

paragraph, with appropriate headings (i.e., Background; Aim; Methodology; Results; Conclusion), and without exceeding the 200-word limit.
Make sure you use abbreviations only after defining them and only if they are truly needed in this section (i.e., if their use saves words).

KEYWORDS: keyword-1, keyword-2, keyword-3, keyword-4, keyword-5

INTRODUCTION

Start your main text here and add your references in the form of a number inside square brackets [1]. You can only use 10 references for the whole manuscript, so be wise in making sure only important arguments and sources are justified throughout the manuscript. Try to use reputable peer-reviewed (preferably PubMed-indexed) resources and avoid (if possible) citing dissertations, theses, grey literature, or websites. Be consistent with the use of abbreviations (once defined, use them without fail). Use *italics* for Latin words (i.e., *in vitro*, *in vivo*, *ex vivo*, *etc*.). If your manuscript presents the findings of research or if it is a review, always ensure your aims are clearly defined at the end of the “Introduction”.

METHODOLOGY

This is a very important section for your manuscript. Make sure you provide a clear description of your methodology, the licences and permissions obtained for the undertaking of your clinical or experimental research, the process of securing the patients’ consent (if applicable), and the statistical analysis performed. This section could be organised into several paragraphs with appropriate subheadings.

If your manuscript is a review, than you can edit this heading (and all subsequent ones) as you see fit and in order to convey your findings in an organized and more effective manner.

RESULTS

In this section, if your manuscript is a research report, please present your findings in an orderly and clear manner. Link them to Tables and Figures wherever needed. Statistical significance should be presented with consistency. Do not discuss your findings; this is something that you will do in the next section.

If your manuscript is a review, than you can edit this heading (and all subsequent ones) as you see fit and in order to convey your findings in an organized and more effective manner.

DISCUSSION

In this section, please discuss the importance and/or the relevance of your findings to those of the existing literature. Do not repeat sentences from the “Results” section. Cite key previous studies, focus on the interpretation of your findings and avoid discussing findings from studies you cannot cite (due to the reference number restriction). Try to explain in an organised manner the importance of your findings and the limitations of the methodology employed. If the word limit allows, offer a glance of what the next steps would be in your research.

CONCLUSION

In two to three sentences maximum, please provide the conclusion of your study and its importance, and avoid exaggerations and platitudes. You should not cite references in this section. This section can also be part of the main text structure of a review.

ACKNOWLEDGMENTS: Please provide here a clearly-written description or expression of gratitude for any help and/or funding received from individuals and/or institutions.

CONFLICT OF INTEREST STATEMENT: This is mandatory to declare; if no conflicts exist, please simply write "None to declare."

© 2025 PHARMAKON-Press

REFERENCES

1. Harun N. H., Mohamad M. F.: The immunomodulatory effects of *Zingiber officinale* (ginger): a systematic review. *Res. J. Pharm. Technol*. 15(8): 3776-3781 (2022).
DOI: 10.52711/0974-360X.2022.00634

2. Yang X. Y., Gong Q. L., Zhao B., Cai Y. N., Zhao Q.: Prevalence of *Cryptosporidium* infection in sheep and goat flocks in China during 2010-2019: a systematic review and meta-analysis. *Vector Borne Zoonotic Dis.* 21(9): 692-706 (2021).
DOI: 10.1089/vbz.2020.2713

3. Tzotzes V., Tzilalis V., Giannakakis S., Saranteas T., Papas A., Mourouzis I., *et al.*: Effects of acute and chronic cadmium administration on the vascular reactivity of rat aorta. *Biometals* 20(1): 83-91 (2007).
DOI: 10.1007/s10534-006-9017-z

4. …
DOI: …

5. …
DOI: …

6. …
DOI: …

7. …
DOI: …

8. …
DOI: …

9. …
DOI: …

10. …
DOI: …

LEGEND TO THE FIGURE / LEGEND TO THE TABLE

Figure 1 / Table 1. This is where the legend to the manuscript's figure or table (depending on your choice) will appear. Please make it as descriptive as possible and make sure all abbreviations appearing in the figure or the table are clearly defined here (even if they also are defined in the main text).

FIGURE 1 / TABLE 1

[place your figure or your table here; ensure high quality and clarity in its content; triple-check for typos; ensure all values (if any) are correct]

© 2025 PHARMAKON-Press